ImageneBio Inc (IMA) (IMA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ImageneBio Inc (IMA) (IMA) trades at $5.61 with AI Score 46/100 (Grade C). ImageneBio Inc is a clinical-stage biotechnology company focused on developing therapies for immunological/autoimmune and inflammatory diseases. Market cap: $63.3M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 9, 2026Analyst Coverage for IMA: IMA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMA: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ImageneBio Inc (IMA) (IMA) Healthcare & Pipeline Overview
ImageneBio Inc (IMA) is a clinical-stage biotechnology company specializing in differentiated therapies for immunological, autoimmune, and inflammatory diseases. Their lead asset, IMG-007, a non-depleting anti-OX40 monoclonal antibody, is in Phase 2b trials for atopic dermatitis, positioning them in a competitive biotech landscape.
What Is the Investment Thesis for IMA?
ImageneBio Inc presents a focused investment opportunity within the biotechnology sector, primarily driven by the clinical advancement of its lead candidate, IMG-007. The Phase 2b trial results for atopic dermatitis will be a critical value inflection point. Positive data could lead to significant upside potential, while negative results could adversely affect the stock. The company's relatively small market capitalization ($0.06B) and low beta (0.55) suggest moderate volatility. The absence of a dividend reflects its focus on reinvesting earnings into research and development. Success in clinical trials and potential partnerships are key growth catalysts. Investors should closely monitor clinical trial outcomes, regulatory milestones, and competitive developments in the atopic dermatitis market.
Based on FMP financials and quantitative analysis
IMA Key Highlights
Lead candidate IMG-007 is in Phase 2b clinical trials for atopic dermatitis, representing a key value driver.
- Market capitalization of $63.3M indicates a small-cap biotechnology company with potential for high growth.
- Beta of 0.55 suggests lower volatility compared to the broader market.
- Focus on immunological/autoimmune & inflammatory (I&I) diseases addresses a large and growing market.
- No dividend reflects the company's focus on reinvesting earnings into research and development.
Who Are IMA's Competitors?
IMA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMA's Key Strengths?
Clinical-stage asset (IMG-007) in Phase 2b trials.
- Focus on a specific niche within the I&I disease market.
- Proprietary non-depleting anti-OX40 monoclonal antibody technology.
What Are IMA's Weaknesses?
Single lead asset creates significant pipeline risk.
- Limited financial resources compared to larger pharmaceutical companies.
- Reliance on successful clinical trial outcomes for value creation.
What Could Drive IMA Stock Higher?
Phase 2b clinical trial results for IMG-007 in atopic dermatitis.
- Potential announcement of strategic partnerships or licensing agreements.
- Continued enrollment and progress in clinical trials.
What Are the Key Risks for IMA?
Financial-distress signal — its Altman Z-Score of 1.43 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-35.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trial outcomes for IMG-007.
- Competition from other companies developing therapies for I&I diseases.
- Regulatory hurdles and delays in obtaining marketing approvals.
- Reliance on a single lead asset creates significant pipeline risk.
- Limited financial resources compared to larger pharmaceutical companies.
What Are the Growth Opportunities for IMA?
- Expansion into Additional Indications: ImageneBio has the opportunity to expand the application of IMG-007 into other immunological and inflammatory diseases beyond atopic dermatitis. The market for autoimmune disease therapies is projected to reach $150 billion by 2028, offering a substantial growth avenue. Success in additional indications would diversify the company's revenue streams and reduce reliance on a single product. This expansion strategy depends on positive clinical trial results and strategic partnerships.
- Strategic Partnerships and Licensing Agreements: ImageneBio can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of IMG-007. Licensing agreements could provide upfront payments, milestone payments, and royalties, bolstering the company's financial position. The market for licensing deals in the biotechnology sector is robust, with numerous opportunities for companies with promising clinical assets. Successful partnerships would validate the company's technology and enhance its market reach.
- Advancement of Pipeline Candidates: ImageneBio can invest in the development of additional pipeline candidates targeting other I&I diseases. A diversified pipeline would mitigate the risk associated with relying solely on IMG-007. The market for novel therapies in the I&I space is constantly evolving, with opportunities for companies that can identify and develop innovative treatments. This strategy requires significant investment in research and development and a strong understanding of the underlying disease mechanisms.
- Geographic Expansion: ImageneBio can expand its clinical trials and commercialization efforts into new geographic markets, such as Europe and Asia. These markets offer significant growth potential due to their large patient populations and increasing healthcare spending. Successful geographic expansion would require navigating regulatory hurdles and establishing partnerships with local distributors. The global market for atopic dermatitis therapies is expected to grow substantially in the coming years, driven by increased awareness and improved access to treatment.
- Acquisition or Merger: ImageneBio could be an attractive acquisition target for larger pharmaceutical companies seeking to expand their presence in the I&I market. A merger or acquisition would provide ImageneBio with access to greater resources and expertise, accelerating the development and commercialization of its pipeline. The biotechnology industry is characterized by frequent mergers and acquisitions, with companies constantly seeking to acquire promising assets and technologies. A successful acquisition would provide significant value to ImageneBio's shareholders.
What Are IMA's Competitive Advantages?
- Proprietary non-depleting anti-OX40 monoclonal antibody technology.
- Clinical-stage asset in Phase 2b trials for atopic dermatitis.
- Focus on a specific niche within the I&I disease market.
What Does IMA Do?
ImageneBio Inc is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapies for immunological, autoimmune, and inflammatory (I&I) diseases. The company's primary focus is on addressing unmet medical needs in these therapeutic areas with differentiated approaches. Founded on the principles of scientific rigor and patient-centric drug development, ImageneBio has rapidly advanced its lead candidate, IMG-007, into Phase 2b clinical trials for atopic dermatitis. IMG-007, a non-depleting anti-OX40 monoclonal antibody, represents a novel approach to modulating the immune system without causing broad immunosuppression. The company's strategy involves identifying promising targets within the I&I disease pathways and developing targeted therapies with improved efficacy and safety profiles. ImageneBio operates out of its headquarters in San Diego, California, and is managed by a team of experienced biotechnology professionals. The company's pipeline is currently centered around IMG-007, with potential for future expansion into other I&I indications. ImageneBio aims to establish itself as a leader in the development of targeted immunomodulatory therapies.
What Products and Services Does IMA Offer?
- Develop differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases.
- Focus on addressing unmet medical needs in the I&I therapeutic areas.
- Advance lead candidate IMG-007 into Phase 2b clinical trials for atopic dermatitis.
- Utilize a non-depleting anti-OX40 monoclonal antibody approach to modulate the immune system.
- Identify promising targets within the I&I disease pathways.
- Develop targeted therapies with improved efficacy and safety profiles.
How Does IMA Make Money?
- Develop and commercialize novel therapies for immunological, autoimmune, and inflammatory diseases.
- Generate revenue through licensing agreements and strategic partnerships with larger pharmaceutical companies.
- Potentially generate revenue through direct sales of approved therapies upon successful commercialization.
What Industry Does IMA Operate In?
ImageneBio operates within the competitive biotechnology industry, specifically targeting the immunological, autoimmune, and inflammatory (I&I) disease market. This market is characterized by high unmet needs and significant growth potential, driven by an increasing prevalence of autoimmune disorders and inflammatory conditions. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying to develop novel therapies. ImageneBio's focus on non-depleting anti-OX40 monoclonal antibodies positions it within a niche segment of immunomodulatory therapies. Success in this market requires strong clinical data, regulatory approvals, and effective commercialization strategies.
Who Are IMA's Key Customers?
- Patients suffering from immunological, autoimmune, and inflammatory diseases, particularly atopic dermatitis.
- Healthcare providers who prescribe and administer these therapies.
- Pharmaceutical companies seeking to license or acquire promising clinical assets.
Forward Outlook
Wall Street analysts project ImageneBio Inc (IMA) revenue of about $340K for fiscal 2026, with EPS near $-3.00. The estimate reflects 3 contributing analysts.
IMA Valuation & Market Position
With a $63.3M market cap, ImageneBio Inc (IMA) sits in the micro-cap segment of the market. Relative to its peer group, IMA's quantitative score of 46/100 is below the peer average of 76/100.
Key Financial Metrics
Return on equity for ImageneBio Inc (IMA) stands at -35.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -78.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 18.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -68.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
ImageneBio Inc (IMA)'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.43 places it in the distress zone, a signal of elevated financial risk.
Company Profile
ImageneBio Inc (IMA) operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Kristin Yarema. IMA has traded publicly since 1998.
IMA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- ImageneBio has recently seen increased insider buying, indicating confidence from key executives about the company's future prospects.
- Community sentiment has turned positive as recent product developments have sparked interest among investors and industry watchers.
- The company's focus on innovative treatments positions it well in a rapidly evolving healthcare landscape, attracting attention from biotech enthusiasts.
- Recent partnerships or collaborations have strengthened its market position, suggesting a growing recognition of its potential.
Bear Case
- Despite positive sentiment, some investors are cautious due to the historical volatility of biotech stocks, which can lead to unpredictable price movements.
- There are concerns about the competitive landscape, with several established players in the same therapeutic areas potentially overshadowing ImageneBio's advancements.
- Community discussions reflect skepticism about the timeline for product approvals, which could delay revenue generation and impact investor confidence.
- Ongoing regulatory challenges in the biotech sector may pose risks to ImageneBio's operational plans and market entry strategies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IMA Latest News
No recent news available for IMA.
IMA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMA.
Price Targets
Wall Street price target analysis for IMA.
IMA MoonshotScore
What does this score mean?
The MoonshotScore rates IMA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Kristin Yarema
CEO
Kristin Yarema serves as the CEO of ImageneBio Inc, bringing extensive experience in the biotechnology industry. Her background includes a strong foundation in pharmaceutical sciences and business strategy. Prior to joining ImageneBio, she held leadership positions at several biotechnology companies, where she oversaw drug development programs and strategic partnerships. Yarema's expertise spans clinical development, regulatory affairs, and commercialization. She holds advanced degrees in both science and business, equipping her with a comprehensive understanding of the biotechnology landscape.
Track Record: Under Kristin Yarema's leadership, ImageneBio has successfully advanced its lead candidate, IMG-007, into Phase 2b clinical trials for atopic dermatitis. She has also overseen the expansion of the company's intellectual property portfolio and the establishment of key partnerships. Her strategic decisions have focused on maximizing the value of IMG-007 and positioning the company for future growth. Yarema's leadership has been instrumental in attracting investment and building a strong team at ImageneBio.
What Investors Ask About ImageneBio Inc (IMA) (IMA) — Healthcare
What does the AI Score mean for IMA?
IMA holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. ImageneBio Inc is a clinical-stage biotechnology company focused on developing therapies for immunological/autoimmune and inflammatory diseases. Their lead candidate, IMG-007, is currently in Phase …
What does ImageneBio Inc do?
ImageneBio Inc is a clinical-stage biotechnology company focused on developing differentiated therapies for immunological, autoimmune, and inflammatory (I&I) diseases. Their primary focus is on IMG-007, a non-depleting anti-OX40 monoclonal antibody currently in Phase 2b clinical trials for atopic dermatitis.
What do analysts say about IMA stock?
As of May 9, 2026, there is limited analyst coverage specifically for ImageneBio Inc (IMA) due to its small market capitalization and clinical-stage nature. However, biotechnology companies in similar stages of development are often evaluated based on the potential of their lead candidates and the strength of their clinical data.
What are the main risks for IMA?
The main risks for ImageneBio Inc (IMA) include clinical trial risk, regulatory risk, and competition risk. Clinical trial risk stems from the possibility that IMG-007 may not demonstrate sufficient efficacy or may exhibit unexpected safety issues in Phase 2b or later-stage clinical trials.
What are the key factors to evaluate for IMA?
ImageneBio Inc (IMA) (IMA) holds an AI score of 46/100 (low). ImageneBio Inc presents a focused investment opportunity within the biotechnology sector, primarily driven by the clinical advancement of its lead candidate, IMG-007. Not financial advice.
How frequently does IMA data refresh on this page?
IMA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IMA's recent stock price performance?
ImageneBio Inc (IMA) (IMA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Clinical-stage asset (IMG-007) in Phase 2b trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMA overvalued or undervalued right now?
ImageneBio Inc (IMA) (IMA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IMA before investing?
Before investing in ImageneBio Inc (IMA) (IMA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- Clinical trial outcomes are inherently uncertain.
- Market conditions and competitive landscape are subject to change.